OPRM1 A118G interacts_with naltrexone
Evidence from:
primary |
all sources
Evidence (6 sources)
Differential sensitivity of human neurons carrying μ opioid receptor (MOR) N40D variants in response to ethanol.
(2020)
PMID:32561311
primary
Analysis of G-allele carriers diagnosed with an AUD responded more strongly to naltrexone, with lower rates of relapse.
confidence: 0.90
Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.
(2017)
PMID:28134463
cited
NTX appears to be most effective in Asp40 carriers
confidence: 0.90
Review: Pharmacogenetics of alcoholism treatment: Implications of ethnic diversity.
(2017)
PMID:28134463
cited
This population may benefit the most from NTX treatment relative to individuals of other ancestries.
confidence: 0.90
individuals with the G/G or A/G genotypes did have reduced relapse rates compared to A/A individuals... Asian Americans... decreased craving... European Americans... increased urge to drink... Naltrexone also reduces euphoric effects
confidence: 0.80
G allele had reduced relapse rates when treated with naltrexone.
confidence: 0.90
Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G.
(2014)
PMID:22862850
cited
Clinical studies revealed that among alcohol dependent patients treated with naltrexone, those with ... G118 allele had better outcome
confidence: 0.91